Trials / Completed
CompletedNCT04456959
InO - A Retrospective Study of UK Patients With Leukaemia
A Retrospective Chart Review of UK Patients With Relapsed/Refractory Acute Lymphoblastic Leukaemia Treated With Inotuzumab Ozogamicin, a Real World Research Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 28 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe the demographics and clinical characteristics, treatment pathway, and effectiveness and safety of inotuzumab ozogamicin in patients with relapsed/refractory B-cell acute lymphoblastic leukaemia treated with inotuzumab ozogamicin in the real-world.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inotuzumab Ozogamicin | Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a recombinant humanised IgG4 kappa CD22-directed monoclonal antibody (produced in Chinese hamster ovary cells by recombinant DNA technology) that is covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide. |
Timeline
- Start date
- 2020-01-06
- Primary completion
- 2021-01-27
- Completion
- 2021-01-27
- First posted
- 2020-07-07
- Last updated
- 2022-09-28
- Results posted
- 2022-03-31
Locations
4 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04456959. Inclusion in this directory is not an endorsement.